TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07533006: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 65 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$309,600

Rescue Site Savings

+$206,400

Unlock Full NCT07533006 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07533006 Rescue Dossier →